Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial
Study Details
This 40-week study examined whether resistance training could reduce lean mass and strength losses during tirzepatide treatment in 120 adults with overweight or obesity π
All participants received tirzepatide, with 59 also completing 3 supervised resistance-training sessions/week π
Key Findings
π Body-weight loss was almost identical: β22.6 kg with tirzepatide alone vs β22.3 kg with resistance training
π₯ Fat-mass loss was also similar: β17.2 vs β18.0 kg
πͺ However, resistance training reduced total lean soft tissue loss from β4.67 to β3.57 kg, preserving around 1.09 kg
𦡠Appendicular lean soft tissue loss was also smaller: β3.55 vs β2.92 kg
ποΈ The biggest difference was muscle function: strength declined with tirzepatide alone but increased substantially with resistance training
π Bench press changed by β4.1 vs +4.7 kg, lat pulldown β4.4 vs +8.6 kg, and knee extension β4.4 vs +5.9 kg
βοΈ Resistance training therefore improved muscle quality and function without compromising the substantial weight or fat loss produced by tirzepatide
π« Blood pressure, glucose, HbA1c and lipids improved similarly in both groups, with no additional cardiometabolic benefit from resistance training
π Lean soft tissue losses occurred primarily during the first ~24 weeks before largely plateauing
Conclusion
For people using tirzepatide or other GLP-1 receptor agonists for weight loss, resistance training can meaningfully reduce lean mass loss, while transforming the trajectory of muscle strength from decline to improvement β
Reference
https://www.nature.com/articles/s41591-026-04752-5

Performance Nutrition Digest is powered by Healthspan Elite β‘οΈ
Healthspan Elite is a science-led sports nutrition range developed in collaboration with leading experts to support athletic performance, recovery, and health.
Use code: TCDIGEST25 for 25% off at https://www.healthspanelite.co.uk/ πͺ





